Eleftha 150mg Injection

Eleftha 150mg Injection is a monoclonal antibody. It is used in the treatment of certain types of breast and stomach cancers that are HER2 receptor positive.

Uses of Eleftha 150mg Injection:

• Gastric Cancer
• Breast Cancer

How does an Eleftha 150mg Injection work?

It targets the HER2 receptor, a protein that is overexpressed on the surface of some cancer cells. Trastuzumab binds to HER2 and inhibits signalling pathways that lead to cell growth and survival, marking the cells for destruction by the immune system and thereby diminishing tumour growth.

How to Use & Dosage

8 mg/kg usually followed by a maintenance dose of 6 mg/kg every three weeks (depending on protocol). Given as an intravenous infusion. First infusions given gradually to watch for any negative reactions.

This medicine is administered intravenously. It is given by a medical professional with special training who works in a hospital or clinic setting.

Ask your paediatrician about giving this medicine to children. This medication is not approved for use in children.

Possible Side Effects:

• Nausea
• Vomiting
• Loss of appetite
• Diarrhea
• Fatigue
• Dizziness
• Sweating
• Stomatitis (mouth sores)
• Hand-foot syndrome
• Cardiotoxicity
• Liver enzyme elevation

Safety Advise:

🫀 Liver

The drug can be toxic especially in patients with prior conditions so periodic tests of liver function are advisable. Please consult your health care provider.

🩺 Kidney

This drug can cause toxicity, especially in patients with pre-existing conditions, so periodic tests for kidney function are advised. Please talk to your health care provider.

🤰 Pregnancy

Eleftha is contraindicated in pregnancy due to the possibility of fetal harm. Please see your doctor.

🤱 Breastfeeding

Breastfeeding is not recommended because the drug may be secreted into breast milk. Please consult your doctor.

Storage Instructions:

Store Eleftha Injection in the refrigerator at 2-8°C. Protect from light and do not freeze.

References

1. Genentech, Inc. HERCEPTIN (Trastuzumab) for Injection: Highlights of Prescribing Information, Including Boxed Warning. U.S. Food and Drug Administration.
2. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of Chemotherapy Plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. New England Journal of Medicine. 2001;344(11):783-792.
3. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in Combination with Chemotherapy versus Chemotherapy Alone for Treatment of HER2-Positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA). The Lancet. 2010;376(9742):687-697.
4. Brunton LL, Knollmann BC, eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education.
5. Tripathi KD. Essentials of Medical Pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers.

Disclaimer:

IHS Enterprises’s primary objective is to guarantee the accuracy, reliability, and specialist review of the information it provides to customers. The contents and information provided on this website are for informational purposes only. They should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician for guidance and any questions you may have about any condition or medication. If you do read anything from IHS Enterprises, please do not discount or delay in seeking competent medical advice. We want to enhance the doctor-patient relationship, not substitute it.

Manufacturer details

Name: Intas Pharmaceuticals Ltd

Address: Chinubhai Centre, Off. Nehru Bridge, Ashram Road, Ahmedabad – 380009. Gujarat. India.

Country of origin: India